This is the most common question and the answer from a mechanistic standpoint is yes, they are complementary rather than redundant : BPC-157 works through nitric oxide and growth factors (gut-mediated) TB-500 works through actin mobilization and cell migration (structural) These are non-overlapping pathways, which is the theoretical basis for combining them
Originally developed to treat type 2 diabetes, these drugs are now widely used to manage obesity
For it to work, you must take it: First thing in the morning on a completely empty stomach
Weight reduction during this stage is generally steady rather than accelerated, reflecting the programs focus on sustainability
While effective in rats, this delivery method is unlikely to be practical or scalable in clinical longevity settings
From Indonesia's perspective, Sreerekha Sreenivasan, General Manager of Novo Nordisk Indonesia, emphasised that this breakthrough is a vital part of a long-term mission to transform obesity care